Brentuximab Vedotin

• Mechanism: Anti-CD30 monoclonal antibody-drug conjugate (delivers MMAE, a microtubule inhibitor)
• Indications:
  • Frontline: In BV + AVD (replacing bleomycin) for stage III–IV cHL
  • Relapsed/Refractory: Post-autologous transplant or as bridging therapy
• Dosing: 1.8 mg/kg IV every 3 weeks
• Key Toxicities:
  • Peripheral neuropathy, neutropenia, fatigue, infusion reactions
• Pharmacist role:
  • Monitor for neurotoxicity and neutropenia
  • Premedication for infusion reactions if needed
  • No pulmonary toxicity (advantage over bleomycin)

Links